|
Merkel cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Self-reported multiple chronic conditions (MCC) and nine instrumental activities of daily livings (IADLs) were assessed in 15 studies of the Dutch National Care for the Elderly Program (TOPICS-MDS).
|
30772903 |
2020 |
|
Multiple Chronic Conditions
|
0.010 |
Biomarker
|
disease |
BEFREE |
Self-reported multiple chronic conditions (MCC) and nine instrumental activities of daily livings (IADLs) were assessed in 15 studies of the Dutch National Care for the Elderly Program (TOPICS-MDS).
|
30772903 |
2020 |
|
Alexithymia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
MDS-16 scores were associated with global psychopathology, traumatic experiences, maladaptive personality features, alexithymia, dissociation, shame feelings, and anxious attachment styles.
|
31012744 |
2019 |
|
Refractory anemias
|
0.010 |
Biomarker
|
disease |
BEFREE |
Given these findings, the requirement of refractory anemia as a diagnostic criterion for MDS/MPN-RS-T should be re-evaluated.
|
30811101 |
2019 |
|
Arthralgia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
By comparison with Crohn's disease, 39 patients with Behcet's-like syndrome and +8-MDS/MPN were significantly older (median 72 [53-78] vs 36 [27-45] years; <i>p</i> = .0002) and more frequently had oral aphtosis (97% vs 5%, <i>p</i> < .0001), skin features (50% vs 10%, <i>p</i> = .0005) and arthralgia (63% vs 20%, <i>p</i> = .03).
|
30457024 |
2019 |
|
Behcet Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Median survival did not differ between patients with Behcet's-like syndrome and +8-MDS/MPN and those with +8-MDS/MPN (<i>n</i> = 103) (47 vs 34 months, <i>p</i> = .61).
|
30457024 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
YWHAE expression was associated with tumor size, lymph node metastasis, and poor patient survival in patients with breast cancer.
|
31001932 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study identified a novel mechanism involving YWHAE-encoded lncRNA, miR-323a-3p and miR-532-5p in regulating HCT116 cell survival and suggested a potential therapeutic avenue for colorectal cancer.
|
31238337 |
2019 |
|
Crohn Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report the 11 cases of +8-MDS/MPN associated with Behcet's-like syndrome and compare them with Behcet's disease and Crohn's disease, pool with literature cases for analysis.
|
30457024 |
2019 |
|
Deglutition Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Dysphagia was identified with SCOPA-AUT question 1 (answer regularly) and was assessed with MDS-UPDRS Part-II, Item 2.3 (Chewing and Swallowing).
|
31344030 |
2019 |
|
Dermatitis, Atopic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Previously, we detected that 14-3-3 protein epsilon (YWHAE) was involved in the pathogenesis of atopic dermatitis (AD) and tyrosinase-mediated pigmentation.
|
31244373 |
2019 |
|
Eczema
|
0.010 |
Biomarker
|
disease |
BEFREE |
Previously, we detected that 14-3-3 protein epsilon (YWHAE) was involved in the pathogenesis of atopic dermatitis (AD) and tyrosinase-mediated pigmentation.
|
31244373 |
2019 |
|
Hypotension, Orthostatic
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Patients with abnormal DAT-SPECT had higher MDS-UPDRS motor score (p = 0.006) and higher prevalence of orthostatic hypotension (p = 0.008).
|
31664065 |
2019 |
|
Disruptive, Impulse Control, and Conduct Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
While levodopa dose (SMD = 0.05, 95% CI: -0.09 -0.19,P = 0.48), Hoehn and Yahr stage(H & Y stage) (SMD =-0.05, 95% CI: -0.14 - 0.04,P = 0.27), MDS-UPDRS Part III score(UPDRS III score) (SMD =-0.05, 95% CI: -0.13 - 0.03,P = 0.24), PD duration (SMD =-0.23, 95% CI: 0.10 - 0.37,P < 0.01)and Mini-Mental Status Examination score (MMSE score) (SMD = 0.10, 95% CI: -0.11 - 0.31,P = 0.33)were not related with PD-ICDs+.
|
31167116 |
2019 |
|
Inflammatory Bowel Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment.
|
31039157 |
2019 |
|
Movement Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
%DET increased and SampEn decreased with increasing Movement-Disorder-Society UPDRS scores, while theta band coherence was significantly correlated with total MDS-UPDRS scores and torque variance.
|
30583273 |
2019 |
|
Myeloproliferative disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Mutations of <i>SF3B1</i> are commonly seen in myelodysplastic syndromes with ring sideroblasts (MDS-RS)and MDS/myeloproliferative neoplasm (MPN-RS-T).
|
31473630 |
2019 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The 5-year cumulative incidence of t-AL/MDS in patients receiving ≥55.8 Gy radiation therapy to the pelvis or spine was 5.0% (95% CI, 0.9-14.9) for osteosarcoma and 10.7% for ES (95% CI, 3.3-23.2).
|
30165126 |
2019 |
|
Speech Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
a cohort study, comparing 10 PD patients with severe speech impairment (MDS-UPDRS item 3.1 ≥ 3) with 10 PD patients with mild speech impairment (MDS-UPDRS item 3.1 ≤ 2), all submitted to STN-DBS.
|
31060986 |
2019 |
|
Progressive supranuclear palsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
The IPD-MDS PSP-RS and PSP-P criteria were unable to distinguish the PSP-RS from the PSP-P phenotypes in this sample.
|
31665686 |
2019 |
|
Tremor
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Tremor pause duration also showed inverse correlation with postural tremor amplitude measured by MDS-UPDRS in OFF (rs = -0.311, p = 0.048) and ON (rs = -0.503, p = 0.020) states, as well as with total MDS-UPDRS Part III score (rs = -0.295, p = 0.009).
|
30348494 |
2019 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our findings indicated that YWHAE promoted cancer progression and chemoresistance in breast cancer cells and can be a potential therapeutic target for breast cancer.
|
31001932 |
2019 |
|
Adult Acute Myeloblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Metformin, a widely used antidiabetic drug, has previously been demonstrated to exert anti-cancer effects in certain hematological malignancies, but its effects on the transformation of myelodysplastic syndromes to acute myeloid leukemia (AML-MDS) remain unclear.
|
31744691 |
2019 |
|
Childhood Acute Myeloid Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Metformin, a widely used antidiabetic drug, has previously been demonstrated to exert anti-cancer effects in certain hematological malignancies, but its effects on the transformation of myelodysplastic syndromes to acute myeloid leukemia (AML-MDS) remain unclear.
|
31744691 |
2019 |
|
Heel toe gait
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
All participants in good-TG group marked "0" for the MDS-UPDRS item 2.13 which addresses freezing event over the past week, whereas 18% (4 of 22) of participants in poor-TG group marked "1".
|
30309805 |
2019 |